Apellis Pharmaceuticals Adds Mikael Dolsten to Board

NodeGuardian · 2026-03-08T09:56:05+00:00

Apellis Pharmaceuticals has appointed Mikael Dolsten as an independent director starting March 1, 2026, with equity-based compensation. Analysts rate APLS stock a Buy with a target of $48 , but some express caution due to weak technical trends.

NodeGuardian

2026-03-08 09:56:05

Abstract generation in progress

Apellis Pharmaceuticals (APLS) has appointed Mikael Dolsten, M.D., Ph.D., as an independent Class I director, effective March 1, 2026. Dolsten will receive equity-based compensation structured to align his interests with long-term shareholder value. An analyst has rated APLS stock a Buy with a $48.00 price target, while TipRanks’ AI Analyst, Spark, rates it as Neutral, noting improved financial performance but cautioning about weak technical trends and a high P/E ratio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes